about
Agomelatine augmentation of escitalopram therapy in treatment-resistant obsessive-compulsive disorder: a case reportAdjunctive agomelatine therapy in the treatment of acute bipolar II depression: a preliminary open label studySuicide during Perinatal Period: Epidemiology, Risk Factors, and Clinical CorrelatesCelecoxib Adjunctive Treatment to Antipsychotics in Schizophrenia: A Review of Randomized Clinical Add-On TrialsPrevalence and clinical features associated with bipolar disorder polypharmacy: a systematic reviewThe Interface between Neuroscience and Neuro-Psychoanalysis: Focus on Brain ConnectivityAtypical Antipsychotics in the Treatment of Acute Bipolar Depression with Mixed Features: A Systematic Review and Exploratory Meta-Analysis of Placebo-Controlled Clinical TrialsA case of obsessive-compulsive disorder successfully treated with agomelatine monotherapyLisdexamfetamine in the treatment of moderate-to-severe binge eating disorder in adults: systematic review and exploratory meta-analysis of publicly available placebo-controlled, randomized clinical trialsAgomelatine beyond borders: current evidences of its efficacy in disorders other than major depressionOut of touch with reality? Social perception in first-episode schizophreniaThe bridge between two worlds: psychoanalysis and fMRI.Thrombocytopenia during valproic acid treatment in young patients with new-onset bipolar disorder.Electroretinographic modifications induced by agomelatine: a novel avenue to the understanding of the claimed antidepressant effect of the drug?Lurasidone in the Treatment of Bipolar Depression: Systematic Review of Systematic ReviewsObsessive-compulsive aspects and pathological gambling in an Italian sample.Altered brain long-range functional interactions underlying the link between aberrant self-experience and self-other relationship in first-episode schizophrenia.Mirtazapine treatment of generalized anxiety disorder: a fixed dose, open label study.Olanzapine augmentation in treatment-resistant panic disorder: a 12-week, fixed-dose, open-label trial.New advances in the treatment of generalized anxiety disorder: the multimodal antidepressant vortioxetine.Neuropsychological functioning in young subjects with generalized anxiety disorder with and without pharmacotherapy.The prevalence and predictors of bipolar and borderline personality disorders comorbidity: Systematic review and meta-analysis.Aripiprazole for relapse prevention and craving in alcohol use disorder: current evidence and future perspectives.An update of safety of clinically used atypical antipsychotics.Agomelatine Increases BDNF Serum Levels in Depressed Patients in Correlation with the Improvement of Depressive Symptoms.The melatonergic system in mood and anxiety disorders and the role of agomelatine: implications for clinical practice.The role of duloxetine in the treatment of anxiety disorders.The relationship between drive to thinness, conscientiousness and bulimic traits during adolescence: a comparison between younger and older cases in 608 healthy volunteersEfficacy and clinical determinants of antipsychotic polypharmacy in psychotic patients experiencing an acute relapse and admitted to hospital stay: results from a cross-sectional and a subsequent longitudinal pilot study.The Role of Inhaled Loxapine in the Treatment of Acute Agitation in Patients with Psychiatric Disorders: A Clinical ReviewThe emerging role of melatonin agonists in the treatment of major depression: focus on agomelatine.Cannabis use and psychosis: theme introduction.Role of melatonin in mood disorders and the antidepressant effects of agomelatine.The role of intranasal oxytocin in the treatment of patients with schizophrenia: a systematic review.The potential of pregabalin in neurology, psychiatry and addiction: a qualitative overview.Treatment of antipsychotic-induced hyperprolactinemia: an update on the role of the dopaminergic receptors D2 partial agonist aripiprazole.Psychopathology, emotional aspects and psychological counselling in infertility: a review.Prevalence and clinical features associated to bipolar disorder-migraine comorbidity: a systematic review.Action verb understanding in first-episode schizophrenia: is there evidence for a simulation deficit?Is there cardiac risk in panic disorder? An updated systematic review.
P50
Q21285010-E94EEAA1-4B93-4BFA-8A88-0C4D37C08465Q24619584-3566D3C7-4BD9-4088-8AA1-311762282D29Q26738486-C941D7D3-5780-4D7D-A0E5-3EEC76A1D080Q26741541-EFBD5DF9-9948-4407-9D46-5A38A0D0523CQ26751363-641D2301-2F2F-4C84-B9A4-C6EFE1C7F6DEQ26766496-88C5D000-F355-4DA4-9459-DC1CC880D19CQ28074759-F80A5B04-C2AD-4FC0-8802-492823BEA337Q28261219-FCC0F929-DEF5-4128-823E-9DAC9B015A2EQ28553322-89BB521C-BDF1-4AE6-8FC0-AAB6EF2BACF4Q28651498-E0150CC4-28EF-4A69-85F3-34085EFE27A1Q30538790-8119B443-2B8B-451C-89C8-531F97C65586Q31002499-1E4B2953-8062-415B-97B1-97AD9C28D32BQ33357011-75237D0B-2B15-4143-9C63-40CFF1B45AE3Q33685314-90797800-A5EC-4403-94BD-AF05CBFA9E25Q33716263-1A05F985-06E0-4CC3-9C5F-B579A16C2469Q33892948-68FF5A62-345A-46A7-A273-C558CA201770Q34048603-C3A445A3-0629-4FC4-9C05-5ACC4202389EQ34560858-3A7A3753-D889-4ADD-9648-0199D64E3DF7Q34564223-184F9D4A-2656-4D46-909C-58583D126782Q34676776-B75C4A32-6739-4A80-A4B0-72A1836C83FCQ34782067-10D787D1-A825-4371-8AE3-6E8327889289Q35924763-88E58A54-BC24-4ED5-BC57-D697B542B4E0Q35995252-B28EAC27-392C-4C04-A91F-86506D52E40AQ36062184-73409AD2-BD1D-4279-BA17-012C59E2F4B5Q36950592-EF61FD7A-4056-4615-80C1-0C48C191E403Q37007350-F9BC38CD-5FA7-457D-B723-A278475977EBQ37062590-5C10374B-4BE1-467A-9305-FCBE3147669BQ37275391-C92373D3-0A57-4887-A9BE-4197DCDA8474Q37579469-852A2A0F-0A0B-4B89-A08A-0569CD882068Q37690847-B1E1CEF3-D35F-4A1C-9D2F-B7110D16A3D7Q37793314-170F4DDF-F61A-4F9E-9F32-48F2D4EB285EQ38020219-892B7870-9AD9-4DF5-A257-63A60D789BF3Q38033191-52F271FB-BAD2-47D1-9075-9D024A01055AQ38087366-1C49E952-29BB-48AC-ABB5-FC28881D965FQ38115597-577CA856-04C3-420C-BCBB-4E7B4A961AACQ38174144-651066B8-FF4A-4A79-B08F-6B66BA0F0910Q38226832-0D3502AC-25AE-45DC-8F30-8FD9BBEF5A2AQ38259208-848DFCA5-2374-44A6-91FC-62ABB7F830C7Q38475567-8CFF9293-8AB0-4097-8ACA-649FF691100BQ38708774-9CC2FE74-ABE7-495C-B715-E1D6674DF00D
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Domenico De Berardis
@ast
Domenico De Berardis
@en
Domenico De Berardis
@es
Domenico De Berardis
@fr
Domenico De Berardis
@nl
Domenico De Berardis
@sl
type
label
Domenico De Berardis
@ast
Domenico De Berardis
@en
Domenico De Berardis
@es
Domenico De Berardis
@fr
Domenico De Berardis
@nl
Domenico De Berardis
@sl
prefLabel
Domenico De Berardis
@ast
Domenico De Berardis
@en
Domenico De Berardis
@es
Domenico De Berardis
@fr
Domenico De Berardis
@nl
Domenico De Berardis
@sl
P106
P1153
7801377515
P2038
Domenico_De_Berardis2
P21
P2798
P31
P496
0000-0003-4415-5058
P569
2000-01-01T00:00:00Z